Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers.

Publication Title

The Journal of clinical investigation

Authors

Parisa Malekzadeh
Anna Pasetto
Paul F Robbins
Maria R Parkhurst
Biman C Paria
Li Jia
Jared J Gartner
Victoria Hill
Zhiya Yu
Nicholas P Restifo
Abraham Sachs
Eric Tran, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USAFollow
Winifred Lo
Robert Pt Somerville
Steven A Rosenberg
Drew C Deniger

Document Type

Article

Publication Date

3-1-2019

Keywords

Animals; Antigens, Neoplasm; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; HLA-A2 Antigen; HLA-DP beta-Chains; Humans; Male; Mice; Mutation; Neoplasms, Glandular and Epithelial; Tumor Suppressor Protein p53

Clinical Institute

Cancer

Specialty

Earle A. Chiles Research Institute

Specialty

Oncology

Recommended Citation

Malekzadeh, Parisa; Pasetto, Anna; Robbins, Paul F; Parkhurst, Maria R; Paria, Biman C; Jia, Li; Gartner, Jared J; Hill, Victoria; Yu, Zhiya; Restifo, Nicholas P; Sachs, Abraham; Tran, Eric; Lo, Winifred; Somerville, Robert Pt; Rosenberg, Steven A; and Deniger, Drew C, "Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers." (2019). Articles, Abstracts, and Reports. 2840.
https://digitalcommons.providence.org/publications/2840